#myxofibrosarcoma

[delveinsight12]

Soft Tissue Sarcoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc.

DelveInsight’s “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Soft Tissue Sarcoma, historical and forecasted epidemiology as well as the Soft Tissue Sarcoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Soft Tissue Sarcoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Soft Tissue Sarcoma Market Forecast

Recent breakthroughs in the Soft Tissue Sarcoma Market:

In October 2022, LIXTE Biotechnology Holdings, Inc. disclosed that the Spanish Agency for Medicines and Health Products (AEMPS) had authorized a Phase 1b/randomized Phase 2 study involving LB-100, the company's primary clinical compound, combined with doxorubicin compared to doxorubicin alone, the established global standard for initial treatment of advanced soft tissue sarcomas (ASTS).

In September 2022, Immutep Limited announced the signing of a Material Transfer Agreement ("Agreement") with the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland. This Agreement enables an investigator-initiated open-label Phase II clinical trial to assess Immutep's lead product candidate, efti, in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) involving up to 40 patients with selected soft tissue sarcomas (STS).

In September 2022, TRACON Pharmaceuticals, Inc. revealed that the U.S. Food and Drug Administration (FDA) had granted fast-track designation for the development of envafolimab (KN035) for patients with locally advanced, unresectable, or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who had progressed on one or two prior lines of chemotherapy.

In September 2022, Avacta Group plc announced that the US Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to the company's lead pre|CISION drug candidate, AVA6000, for the treatment of soft tissue sarcoma. AVA6000 is a modified form of the chemotherapy drug doxorubicin, utilizing the pre|CISION technology to predominantly activate within the tumor, aiming to enhance safety, tolerability, and efficacy while sparing healthy tissue exposure.

In May 2022, Immix Biopharma, Inc., reported positive interim study data demonstrating that after one cycle of treatment, the company's lead candidate IMX-110 resulted in 75% survival compared to 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. IMX-110 was evaluated against approved drugs for STS treatment, with Trabectedin administered according to Meco et al., 2003 (trabectedin monotherapy treatment arm), and IMX-110 at a dose of 2.0 mg/kg.

In April 2022, Telix Pharmaceuticals Limited announced a licensing agreement with Eli Lilly and Company ("Lilly") granting Telix exclusive worldwide rights to develop and commercialize radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial focus will be on a rare cancer type known as soft tissue sarcoma (STS).

Some of the key facts of the Soft Tissue Sarcoma Market Report: 

The Soft Tissue Sarcoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

According to the revised statistical estimates of the American Cancer Society (2022), there were about 13,190 newly diagnosed cases of soft tissue sarcoma and approximately 5,130 deaths (2,740 males and 2,390 females) due to soft tissue sarcoma in the US. 

Key Soft Tissue Sarcoma Companies: Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc., and others

Key Soft Tissue Sarcoma Therapies: Camsirubicin, Lurbinectedin, Liposomal Annamycin (L-Annamycin), AL3818, YH001, CFT8634, Olaratumab + Doxorubicin, Tazemetostat + Doxorubicin HCl, Niraparib, Seclidemstat, Tinostamustine (EDO-S101), HFB301001, Tigilanol Tiglate, Pembrolizumab, Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy, L19TNF and DOXORUBICIN, doxorubicin with AGEN1884 and AGEN2034, APX005M, MGCD516, and others

The Soft Tissue Sarcoma epidemiology based on gender analyzed that Males are slightly more affected in the case of Soft Tissue Sarcoma

The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Soft Tissue Sarcoma pipeline products will significantly revolutionize the Soft Tissue Sarcoma market dynamics.

 Soft Tissue Sarcoma Overview

Soft tissue sarcoma is a relatively uncommon form of cancer that originates in the soft tissues of the body, including muscles, tendons, fat, blood vessels, and nerves. While it can affect individuals of all ages, it is more frequently diagnosed in adults. The precise causes of soft tissue sarcoma are not always clear, though certain risk factors have been identified, such as exposure to radiation, specific genetic conditions, and previous treatment with certain chemotherapy drugs.

The symptoms of soft tissue sarcoma can vary depending on the size and location of the tumor. Common indicators may include the presence of a noticeable lump or swelling in the affected area, pain or tenderness, restricted mobility, and sometimes a sensation of pressure or fullness. Since these symptoms can resemble those of various other conditions, it is crucial to seek medical attention if they persist or worsen.

The diagnosis of soft tissue sarcoma typically involves a combination of imaging techniques such as MRI, CT scans, and ultrasounds to identify the presence and location of the tumor. Following this, a biopsy is performed, in which a small tissue sample is extracted and examined under a microscope to ascertain whether the growth is malignant or benign.

Get a Free sample for the Soft Tissue Sarcoma Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-market 

Soft Tissue Sarcoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Soft Tissue Sarcoma Epidemiology Segmentation:

The Soft Tissue Sarcoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Soft Tissue Sarcoma Incident Cases 

Soft Tissue Sarcoma Gender-specific Incident Cases 

Soft Tissue Sarcoma Type-specific Incident Cases 

Soft Tissue Sarcoma Age-specific Incident Cases 

Soft Tissue Sarcoma Stage-specific Incident Cases 

Incident Cases of Soft Tissue Sarcoma by Extremities 

Download the report to understand which factors are driving Soft Tissue Sarcoma epidemiology trends @ Soft Tissue Sarcoma Epidemiology Forecast

Soft Tissue Sarcoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Soft Tissue Sarcoma market or expected to get launched during the study period. The analysis covers Soft Tissue Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Soft Tissue Sarcoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Soft Tissue Sarcoma Therapies and Key Companies

Camsirubicin: Monopar Therapeutics

Lurbinectedin: Jazz Pharmaceuticals

Liposomal Annamycin (L-Annamycin): Moleculin Biotech, Inc.

AL3818: Advenchen Laboratories, LLC

YH001: Tracon Pharmaceuticals Inc.

CFT8634: C4 Therapeutics, Inc.

Olaratumab + Doxorubicin: Eli Lilly and Company

Tazemetostat + Doxorubicin HCl: Epizyme, Inc./Ipsen

Niraparib: GlaxoSmithKline

Seclidemstat: Salarius Pharmaceuticals, LLC

Tinostamustine (EDO-S101): Mundipharma Research Limited

HFB301001: HiFiBiO Therapeutics

Tigilanol Tiglate: QBiotics Group Limited

Pembrolizumab: Merck Sharp & Dohme LLC

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy: Polaris Group

L19TNF and DOXORUBICIN: Philogen S.p.A.

doxorubicin with AGEN1884 and AGEN2034: Agenus Inc

APX005M: Apexigen America, Inc.

MGCD516: Mirati Therapeutics Inc.

Discover more about therapies set to grab major Soft Tissue Sarcoma market share @ Soft Tissue Sarcoma Treatment Landscape 

Soft Tissue Sarcoma Treatment Market

Treatment for soft tissue sarcoma is typically personalized, taking into account factors such as the tumor's type, location, stage, and the patient's overall health. The primary methods of treatment include surgery, radiation therapy, and chemotherapy, which may be used alone or in combination, depending on the specific circumstances. Surgery is often the first-line treatment for localized soft tissue sarcoma, aiming to excise the tumor along with a margin of healthy tissue to reduce the risk of recurrence. In some cases, reconstructive procedures may be necessary to preserve function and appearance.

Radiation therapy involves using high-energy rays to target and eliminate cancer cells or shrink tumors, either before surgery to make the tumor more manageable or as a standalone treatment for tumors that cannot be operated on. It may also be employed post-surgery to lower the risk of local recurrence. Chemotherapy may be recommended for certain types of soft tissue sarcomas that are prone to metastasis. This treatment entails the use of drugs to kill or slow the growth of cancer cells and is typically administered in cycles to allow for recovery between sessions.

In recent years, targeted therapies and immunotherapy have emerged as promising avenues for treating soft tissue sarcomas, particularly in cases where traditional treatments have been ineffective. These innovative treatments are designed to specifically target molecules involved in tumor growth or stimulate the body's immune system to combat cancer cells. A multidisciplinary team comprising oncologists, surgeons, radiation oncologists, and other specialists collaborates to devise the most suitable treatment plan for each patient. Regular follow-ups and monitoring are essential to detect any signs of recurrence or potential treatment-related side effects. Although treating soft tissue sarcoma can be challenging, ongoing advancements in medical research and personalized treatment approaches offer hope for improved outcomes and enhanced quality of life for affected individuals.

To know more about Soft Tissue Sarcoma companies working in the treatment market, visit @ Soft Tissue Sarcoma Clinical Trials and Therapeutic Assessment

[tawshadawn]

ME, yes this is me 8 years ago ... Facebook memories! 💙🦋💚⠀ ⠀ Did you know that I beat Sarcoma (myxofibrosarcoma) cancer in 2011?? Not all cancers are created the same. In fact, all cancers are created different, react different, metastasize different and respond different. Although the sarcoma cancer is a very different cancer than the clear cell ovarian cancer I’ve been diagnosed with, they both are rooted from my genetic mutation PIK3CA which can cause many types of different cancers. I believe if we can fix my genetic mutation (focus on the root cause) then we can stop these cancers from attacking me in the first place. ⠀ ⠀ The sarcoma cancer that attacked my body was in my left thigh. This photo to me represents a feeling of RESPECT. In order to come to some kind of terms with your disease there needs to be some sort of respect of what the disease is and how we can live our fullest “beyond” the disease. ⠀ ⠀ This photo was taken around a year after my last radiation treatment to knock it out. The square tan line on my left thigh, along with incision scar down the center of it is very apparent. 🦵🏼👀⠀ ⠀ Today @cbcedmonton is coming to my home to film my story. I’ve been advocating to get access to this drug for months now, with no luck so I’m hoping through awareness, someone, somewhere out there listening 🔊 to my story can help me in this fight to survive. ⠀ ⠀ Much love always. xo T⠀ #ovariancancer #ovariancancerawareness #sarcomacancer #myxofibrosarcoma #rarebird #pik3ca #findtheroot #carribeancruise #manymoonsago #youngandfun ⠀ ⠀ (at Edmonton, Alberta) https://www.instagram.com/p/B8g34l2AJds/?igshid=p0ff93qz6703

[thatclimbergirl]

My professor wants me to submit an abstract to present research at the nuclear medicine national conference?

[dr-ladybird]

Tagged by @moniesmonsters

Rules: Tag 9 people you want to get to know better/catch up with, and answer the questions below!

Last song: My playlist’s stopped on The Bonnie Ship the Diamond (Gaelic Storm version)

Three ships: Ooh, so for Mass Effect I’ll go with player character x Jaal. Not fussy about Ryder’s gender but preferably one of the more mature and sensible ones. 

Locked Tomb, sorry for being basic but Gideon x Harrow (in a “I hope they get their shit together and have a healthy relationship” way.)

Almost anything you can ship or might want to ship in Elden Ring is some flavour of crack, so I’m going to go completely off the wall and claim that Oleg and Margit had a discreet romantic relationship when they were coworkers. (And Oleg swears he caught the king eyeing him up a few times... he must just be that pretty, eh?)

Currently Reading: textbooks :( ok so fat cancers are divided into well differentiated/dedifferentiated aka normal/bad normal (MDM2 amplified), myxoid aka gooey/bad gooey (DDIT3 rearranged, usually with FUS), and pleomorphic aka really bad (multiple genes broken in multiple messy ways), and the gooey versions look far too much like myxofibrosarcoma and low grade fibromyxoid sarcoma (which are not the same thing)... you get the idea.

Last Movie: Hmm, I haven’t seen a movie in ages... probably the new Dune? That was brilliant, excellent acting and setting, I’m very pleased they were brave enough to go full political. My brother and his wife kept arguing over whether Timothee Chalumet or Oscar Isaacs was more attractive (me, I vote for Jason Momoa)

Craving: a coherent understanding of bone and muscle tumours

Tagging @pigeontheoneandonly @huggingtentacles @bronzeagelove @dr-jekyl @inquartata30 @miniature-space-hamster

[polyacrylamidepensieve]

In the news today re: studying bone and soft tissue tumors for pathology boards

“Enchondroma. Osteochondroma. Osteosarcoma. Chondrosarcoma. Osteoblastoma. Chondroblastoma. Osteoid osteoma. I’m bout to cut a bitch”

“Wtf do you mean Parosteal osteosarcoma and periosteal osteosarcoma are not the same thing”

“WTF DO YOU MEAN MYXOFIBROSARCOMA AND FIBROMYXOID SARCOMA ARE NOT THE SAME THING”

“FUCK ALL OF THIS IM GOING BACK TO BED”

[juniperpublisherscasestudies]

Juniper Publishers- Open Access Journal of Case Studies

Challenges in the Management of Metastatic Soft Tissue Sarcomas: where are we going?

Authored by Luca Paoluzzi

Keywords

Keywords: Soft tissue sarcoma; Next generation sequencing; Larotrectinib; Tazemetostat; Check-point inhibitors; Leiomyosarcoma; Liposarcoma; Undifferentiated sarcoma

Abbreviations: STS: Soft Tissue Sarcoma; LMS: Leiomyosarcoma; LPS: Liposarcoma; UPS: Undifferentiated Pleomorphic Sarcoma; ASPS: Alveolar Soft Part Sarcoma; PEComa: Perivascular Epithelioid Tumor; DDLPS: Dedifferentiated Liposarcoma; NGS: Next Generation Sequencing; TMB: Tumor Mutational Burden; MFS: Myxofibrosarcoma; TRK: Tropomyosin Kinase; ES: Epithelioid Sarcoma

Introduction

Soft tissues sarcomas (STS) are a heterogeneous group of diseases with more than 70 entities described in the last WHO classification [1] and 13,040 estimated new cases in the US in 2018 [2]; the most common subtypes, excluding gastrointestinal stromal tumors, are represented by leiomyosarcoma (LMS), liposarcoma (LPS) and undifferentiated/unclassified sarcomas. Four new drugs have been approved by the FDA for the treatment of metastatic STS since 2012: olaratumab in the first line setting, in combination with doxorubicin; [3] pazopanib, a tyrosine kinase inhibitorfor all subtypes but adipocytic tumors [4]; trabectedin for LMS and LPS [5]; eribulin for LPS [6] (the last three drugs were all approved for after prior chemotherapy).

During the last several years it has become progressively more clear that different subtypes of STS may respond differently to distinct treatments; one of the oldest examples in this regard comes from angiosarcoma that is known for its sensitivity to paclitaxel; additional examples include alveolar soft part sarcoma (ASPS) for its sensitivity to tyrosine kinase inhibitors and, most recently, to check point inhibitors; malignant perivascular epithelioid tumors (PEComa) that may respond to mTOR inhibition with drugs such as sirolimus or inflammatory myofibroblastic tumors to crizotinib and so on.

Immunotherapies based on check-point inhibitors are currently revolutionizing the way we treat multiple malignancies. The first demonstration of efficacy of immunotherapy in cancer actually comes from a patient with a neck sarcoma, back in 1891, who had a complete response after injection of a culture of streptococcus erysipelas [7]. Two recent prospective phase 2 studies explored the activity of checkpoint inhibitors in STS: the response rate was 18% (7/40) for pembrolizumab alone [8], 5% for nivolumab alone (2/38) and 16% (6/38) for nivolumab plus ipilimumab [9].

During the last few years, next generation sequencing (NGS) has shown the potential to impact the diagnosis and treatment of STS positively; a retrospective analysis of 5,635 patients worldwide included 56 different histologies; subjects have been profiled for 405 cancer-related genes in the DNA and 265 gene rearrangements in the RNA; 1165 fusions and more than 60,000 mutations were found; up to 42% of patients had some type of alterations that made them eligible for a targeted therapy in the context of a "basket" trial such as the NCI-MATCH trial [10].

Additional useful information from NGS analysis is represented by the tumor mutational burden (TMB); TMB has been associated with response to check-point inhibitors in multiple malignancies such as melanoma and non-small cell lung cancer. In an analysis of 100,000 human cancer genomes, sarcomas generally have showed relatively low TMB, but cases with high TMB have also been reported [11], this information may be of particular interest in less frequent histologies for which genomic data is very limited.

A comprehensive and integrated genomic characterization of adult STS has been recently published by the Cancer Genome Atlas Research Network [12]: 206 sarcomas, representing 6 major types were analyzed through a multi-platform molecular approach. Copy number changes with low mutational loads and only a few genes highly recurrently mutated were noted across all subtypes (TP53, ATRX, RB1). Generally, deletions and mutations in tumor suppressor genes were more common than amplifications and mutations in oncogenes. Specific pathway activation with distinct molecular subtypes associated with clinical outcomes were found in dedifferentiated liposarcoma (DDLPS) and soft tissue LMS; furthermore, a study of the tumor immune microenvironment through DNA methylation and mRNA profiling revealed immune cell infiltration in genomically complex DDLPS, LMS, undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS). Of note, objective responses to check-point inhibitors in prospective clinical trials have been reported in the aforementioned subtypes with 4/10UPS and 2/10LPS responding to pembrolizumab, 2LMS, 1MFS, 2UPS out of 38 patients responding to nivolumab + ipilimumab, 1LMS out of 38 patients responding to nivolumab alone. Additional histologies that showed responses in these trials included one angiosarcoma treated with nivolumab + ipilimumab, one ASPS treated with nivolumab alone and one synovial sarcoma who received pembrolizumab [8,9].

Classically, cancer patients have been enrolled into clinical trials based on specific histologic and age criteria. Basket trials with a focus on peculiar genomic characteristics are now inducing a paradigm shift in the treatment of many cancers; rare cancers such as STS will especially benefit from this new trial design because of the obvious challenges in developing prospective studies in uncommon disease.

One of the most successful examples in this regard is the clinical development of larotrectinib, a potent and selective small- molecule inhibitor of tropomyosin kinase (TRK) proteins. In a cohort of 55 patients with 17 different types of cancers including 18 patients with STS, larotrectinib showed objective responses in 75% of patients with 7 complete responses. Of note, two pediatric patients with locally advanced fibrosarcoma were able to undergo limb-sparing surgery with curative intent after preoperative treatment [13]. Other stories such as the development of MDM2 or CDK4 inhibitors for dedifferentiated LPS, have been less successful so far, but multiple target therapies are in clinical development. Additional treatment strategies include targeting the epigenetic cellular machinery; one example comes from the use of EZH2 inhibitors in INI1 negative tumors such as epithelioid sarcoma (ES). ES is notoriously a very aggressive and chemo-resistant STS subtype for which only surgical resection has shown to be potentially curative to date. An ongoing phase 2 multicenter trial is exploring the activity of the EZH2 inhibitor Tazemetostat in patients with INI1 negative tumors including ES; preliminary results presented at the 2017 ASCO meeting showed one partial response in ES [14]. Interestingly, one transient partial response to nivolumab and pazopanib has been noted in a patient with ES in a recent retrospective series [15].

Conclusion

In conclusion, new genomic tools and trial designs are refining the diagnosis and treatment of STS increasing the knowledge on these heterogeneous diseases and providing new hope to patients.

For more articles in Open Access Journal of Case Studies please click on: https://juniperpublishers.com/jojcs/index.php

[crimsonpublishers-neurosurgery]

Myxofibrosarcoma of Base of Skull in Paediatric Age Group: A Case Report: Crimson Publishers

Myxofibrosarcoma of Base of Skull in Paediatric Age Group: A Case Report by Zafar Ahmed Sheikh in Techniques in Neurosurgery & Neurology: Crimson Publishers_Journal of Neurology

Myxofibrosarcoma is a common sarcoma affecting extremities of elderly age group. It rarely affects the younger age group and the head neck reg ion. It exhibits an infiltrative growth pattern and has a high local recurrence rate. We report a 14 year old patient with a myxofibrosarcoma of base of skull. The patient’s age and clinical presentation favored a bed side diagnosis of a dermoid cyst or langerhans cell histiocytosis, radiology was suggestive of an intraosseous hemangioma and surgical pathology favored a low grade Osteosarcoma. However, tissue immunohistochemistry clinched the diagnosis of a Myxofibrosarcoma. He underwent a near total excision with adjuvant radiotherapy and remains recurrence free at one and a half year follow up. Tissue immuno chemistry played a pivotal role in the management of our patient. We have attempted to bring forward the pertinent neurosurgical issues related to the management of this common soft tissue sarcoma which is rarely encountered by Neurosurgeons.

https://crimsonpublishers.com/tnn/fulltext/TNN.000530.php

For more open access journals in Crimson Publishers please click on link: https://crimsonpublishers.com/

For more articles in Journal of Neurosurgery please click on link: https://crimsonpublishers.com/tnn/

Follow On Linkedin : https://linkedin.com/in/chyler-henley-ba9623175Follow On Medium : https://medium.com/crimson-publishers/crimson-publishers-journals-f29e22da8f5c

[moleculardepot]

MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. A new interesting article has been published in Cancers (Basel). 2019 May 15;11(5). pii: E677. doi: 10.3390/cancers11050677.

[tumimmtxpapers]

Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma.

Related Articles Peptide vaccinations elicited strong immune responses that were reboosted by anti-PD1 therapy in a patient with myxofibrosarcoma. Cancer Immunol Immunother. 2019 Dec 18;: Authors: Tsukahara T, Watanabe K, Murata K, Takahashi A, Mizushima E, Shibayama Y, Kameshima H, Hatae R, Ohno Y, Kawahara R, Murai A, Nakatsugawa M, Kubo T, Kanaseki T, Hirohashi Y, Terui T, Asanuma H, Hasegawa T, Sato N, Torigoe T Abstract Peptide-based immunotherapy does not usually elicit strong immunological and clinical responses in patients with end-stage cancer, including sarcoma. Here we report a myxofibrosarcoma patient who showed a strong clinical response to peptide vaccinations and whose immune responses were reboosted by anti-PD1 therapy combined with peptide vaccinations. The 46-year-old man showed a strong response to the peptide vaccinations (papillomavirus binding factor peptide, survivin-2B peptide, incomplete Freund's adjuvant, and polyethylene glycol-conjugated interferon-alpha 2a) and subsequent wide necrosis and massive infiltration of CD8+ T cells in a recurrent tumor. The patient's immune responses weakened after surgical resection; however, they were reboosted following the administration of nivolumab combined with peptide vaccinations. Thus, anti-PD1 therapy combined with peptide vaccinations might be beneficial, as suggested by the observations in this sarcoma patient. PMID: 31853575 [PubMed - as supplied by publisher] http://dlvr.it/RLdzPz

[cancersfakianakis1]

Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma

Abstract

Myxofibrosarcoma (MFS) is an aggressive sarcoma that requires novel therapeutic approaches to improve its clinical outcome. Cell lines are a valuable tool for pre-clinical research; however, there is a lack of patient-derived cell lines of MFS available from public cell banks. This study aimed to develop a patient-derived cell line of MFS. A cell line designated NCC-MFS1-C1 was established from the primary tumor tissue of an 82-year-old male patient with MFS. The short tandem repeat pattern of NCC-MFS1-C1 cells was identical to that of the original tumor, but distinct from that of any other cell lines in public cell banks. NCC-MFS1-C1 cells were maintained as a monolayer culture for over 20 passages in 19 months; the cells exhibited spindle-like morphology, continuous growth, and ability for spheroid formation and invasion. Genomic assay showed that NCC-MFS1-C1 cells had gain and loss of genetic loci. Proteomic profiling revealed that the original tumor and the derived NCC-MFS1-C1 cells had similar, but distinct protein expression patterns. Screening of anti-cancer drugs in NCC-MFS1-C1 cells identified five candidate drugs for MFS. In conclusion, we established a novel MFS cell line, NCC-MFS1-C1, which could be used to study tumor development and effects of anti-cancer drugs.

http://bit.ly/2te52hs

[tawshadawn]

📸:: Photo taken last summer doing my research! ⠀ Not once have I asked “why me??” —because in reality it could happen to any of us.. so WHY NOT ME?”⠀ ⠀ In 2010 I was diagnosed with stage 2 MyxofibroSarcoma Cancer on my left thigh. At first I didn’t think there would be a connection between that cancer and my new diagnosis of Stage 3b Clear Cell Ovarian Cancer. ⠀⠀ ⠀⠀ BUT... ⠀⠀ ⠀⠀ I’m a research girl, it’s in my personality to feel comfort in knowing anything and everything about my diagnosis. So when I was first diagnosed with this “ovarian cancer” I started researching. The best treatments, genetic influences, heredity, etc. ⠀⠀ ⠀⠀ Then I found something.. recently researchers have found a genetic mutation called PIK3CA that links sarcoma cancers to “specifically” Clear Cell Ovarian cancers. WHAT??? This was amazing to me. Is this it!?? 💭🔑 Is this my answer??! The key that can reverse my 22% prognosis. ⠀⠀ ⠀⠀ Soon after I was diagnosed, I spoke to my gyny-oncologist about this and she agreed I should have genetic testing done. After a whole lot of push, I am now soon to have access to this combination of drugs that could correct this mutation. Thank you to @novartis Canada 🇨🇦 ⠀ ⠀⠀ I believe my life depends on these inhibitor drugs. Although they have never been tested in ovarian cancer human trials, they do show promise in correcting the PIK3CA mutation; which I believe is the root cause of both my cancers. ⠀ ⠀ I will never stop pushing for my life. I am a brave warrior and I will never give up! ⠀ ⠀ #cancer #sarcomacancer #ovariancancer (at Edmonton, Alberta) https://www.instagram.com/p/CAs1rV_A7RC/?igshid=114ss6h9sg32a

[sisiad]

Integrated genetic and epigenetic analysis of myxofibrosarcoma

http://dlvr.it/QbptlJ

[itsmedicinesfakianakis]

Myxofibrosarcoma in Head and Neck: Case Report of Unusually Aggressive Presentation

Publication date: Available online 16 August 2017 Source:Journal of Oral and Maxillofacial Surgery Author(s): Anastasiya Quimby, Abigail Estelle, Arun Gopinath, Rui Fernandes Myxofibrosarcoma (MFS) is a malignant fibroblastic tumor that primarily affects lower and upper extremities. It is usually described as a slow growing tumor with high recurrence rates but low metastatic potential. Reported incidence of head and neck MFS is 2-4% rarely presenting with distant metastases[1, 2]. We present a case of maxillary MFS in a 72-year-old woman whose disease progression followed an atypical course with an extremely rapid rate of growth and early pulmonary and central nervous system lesions. Due to pulmonary symptoms as initial presentation, arriving at a final diagnosis was a challenge. Various diagnostic modalities and multidisciplinary collaboration were required. The disease course and management are outlined. To our knowledge, this is the first case of MFS originating in the maxillary alveolus with multiple metastases including brain and lungs in the early course of the disease. http://ift.tt/2v3Bkdv from OtoRhinoLaryngology - Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2fNi7Ll

[tawshadawn]

I love New York.. well specifically Soho❤️❤️ ⠀ In January 2011 I was diagnosed with a cancer called Myxofibrosarcoma, my treatment was 7-1/2 weeks of daily radiation. Our kids were 5 and 6 years old and to celebrate “mom’s done treatment and cancer free” we went on a magical trip to Disneyland!!💫💫 It truly is the happiest place on earth.🤗⠀ ⠀ What does this have to do with New York City?? ⠀ ⠀ Well— in January 2018 I was diagnosed with stage 3 ovarian cancer, my treatment was one full year of 💉🙄 chemotherapy. Our kids are now 13 and 14 years old and this time to celebrate “mom’s done treatment and cancer free” we booked New York!! #ohyababy Jason and I have been to NYC a few times but this would be the kids first experience. ⠀ ⠀ 👻 SURPRISE!!!! Eleven days before we were set to fly out and celebrate LIFE, we got the news. My cancer returned with a vengeance and I restarted chemotherapy on the Monday (6days before we’re supposed to leave). ⠀ ⠀ Who would have thought?? Not us!! I knew my prognosis wasn’t great but I just thought we’d have more time!? I guess it’s just one more confirmation that we don’t get to choose our challenges.. only how we respond to them. ⠀ ⠀ The trip will still be AMAZING.. just a little slower, a few pain killers and maybe a trip back to the hotel for a nap now and then. Regardless— we are creating moments, having fun and making memories. #lookoutnewyorkcity #thesparksareintown #tripupdatescoming⠀ ⠀ ⠀ (at SIXTY Soho) https://www.instagram.com/p/BzXAIYvIeV1/?igshid=186aaqoqxx1fv

[tawshadawn]

Today was National Cancer Survivor Day in the U.S.A! I survived two cancers. ⠀⠀ 🦋March 24 2011 I completed my last of 35 radiation treatments for stage 2 Myxofibrosarcoma Cancer. ⠀⠀ 🦋February 21 2019 I completed my last of 13 months of chemotherapy for stage 3 Clear Cell ovarian cancer. ⠀⠀ ⠀⠀ When I was diagnosed with a second cancer almost 7 years to the day apart I was shocked. How could this happen? Is this really my life? I had what “I call” a soul shift. I am a different person today than I was before my ovarian cancer diagnosis. I see life (and death) through different eyes. Everything is beautiful and everything is a blessing. ⠀⠀ ⠀⠀ I don’t hate my body for getting cancer. I love my body for being strong enough to endure the surgery and treatment I needed to heal. I embrace the potential of my body as it is a force of resilience.⠀⠀ ⠀⠀ I share my journey and my story because I know in my heart that peace is in all of us if we allow it to be there. No jealousy, no hate, no envy.. an unexplainable calm of love and acceptance. ⠀⠀ ⠀⠀ I advocate because I am a voice for those who didn’t make it. I advocate to uplift and encourage those who are struggling, that no matter how hard your journey you can do hard things. I advocate because we are not alone.. we all struggle but when we join forces we can all overcome together. ⠀⠀ ⠀⠀ You are stronger than you think. . you will feel like you can’t fight anymore, but YOU CAN. Just remember that you have already come this far. You WILL get pushed down but you’ll also GET BACK UP. Don’t ever give up!! #wegotthis #wearesurvivors⠀⠀ ⠀⠀ What would you do different if you knew your life was going to end soon. What would you change? ⠀⠀ (at Edmonton, Alberta) https://www.instagram.com/p/ByPKKNgo9Gn/?igshid=1rlethrbpzi5r

[tawshadawn]

April 2011. Photos from out Disneyland trip to celebrate completing treatment for my sarcoma cancer. ⠀ Not once did I ask “why me??” WHY NOT ME? Here’s the thing, none of us are special🤔 or wait, maybe we’re all special. Either way you look at it, it could happen to any of us, including you. ⠀ ⠀ In 2010 I was diagnosed with stage 2 MyxofibroSarcoma Cancer on my left thigh. At first I didn’t think there would be a connection between that cancer and my new diagnosis of Clear Cell Ovarian Cancer. ⠀ ⠀ BUT... ⠀ ⠀ I’m a research girl, it’s in my personality to feel comfort in knowing everything and everything about stuff. So when I was first diagnosed with this ovarian cancer I started researching. The best treatments, genetic influences, heredity, etc. ⠀ ⠀ Then I found something.. recently researchers have found a genetic link called ARID1A to sarcoma cancers and “specifically” Clear Cell Ovarian. WHAT??? This was amazing to me. This is it!! This is my answer!! The key that can reverse my 22% prognosis. ⠀ ⠀ Soon after I was diagnosed, I spoke to my gyny-oncologist about this and she agreed I should have genetic testing done. What frustrates me is that none of these genetic testing companies test for ARID1A and no one seems to know where I can get the testing done!?! 🤦🏼‍♀️ My guess is that it’s so rare and not enough knowledge for it to be cost effective.🤷🏼‍♀️⠀ ⠀ So my search continues. I’ve read online that the University of British Columbia Hospital has done intense research on ARID1A and Clear Cell Ovarian cancer. So I’m looking into who I can contact there and see if I can get some answers or at the very least be connected to the right people that can help. ⠀ ⠀ Because I was diagnosed at stage 3, I believe my life depends on this test. I’ve read that there are inhibitors that are showing promise to helping with survival. Any information they can give me would be greatly appreciated.⠀ ⠀ I will never stop pushing for my life. I am a brave warrior and I will never give up! @universityofbc @university_of_british_columbia @uofbritishcolumbia #cancer #sarcomacancer #ovariancancer (at Disneyland California) https://www.instagram.com/p/Bx-UTrEIvkK/?igshid=1eq0f283ffy0c